Mathieu Boudreau
Direttore operativo presso FORESEE PHARMACEUTICALS CO., LTD.
Profilo
Mathieu Boudreau is currently the Chief Operating & Business Officer at Foresee Pharmaceuticals Co., Ltd.
Previously, he worked as the Senior Director-Corporate Development & Licensing at Telesta Therapeutics, Inc. from 2014 to 2016.
He also held positions as the Director-Business Development at Aegera Therapeutics, Inc., Director-Business Development & Strategic Planning at Pharmascience, Inc., and Director-Search & Evaluation Business Development at Pendopharm, Inc. Dr. Boudreau holds a doctorate degree from McGill University and an undergraduate degree from the University of Montréal.
Posizioni attive di Mathieu Boudreau
| Società | Posizione | Inizio |
|---|---|---|
| FORESEE PHARMACEUTICALS CO., LTD. | Direttore operativo | - |
Precedenti posizioni note di Mathieu Boudreau
| Società | Posizione | Fine |
|---|---|---|
| TELESTA THERAPEUTICS INC | Corporate Officer/Principal | 01/12/2016 |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Corporate Officer/Principal | 01/01/2011 |
Pharmascience, Inc.
 Pharmascience, Inc. Pharmaceuticals: MajorHealth Technology Pharmascience, Inc. manufactures and distributes generic and drug products. It offers liquids, tablets, capsules, suppositories, powders, and ophthalmic. The company was founded by Morris Goodman and Ted S. Wise in 1983 and is headquartered in Montr?al, Canada. | Corporate Officer/Principal | - |
Pendopharm, Inc.
 Pendopharm, Inc. Pharmaceuticals: MajorHealth Technology Pendopharm, Inc. is engaged in licensing, partnering, developing and marketing prescription medicines. Its products include Lax-A, helixia, Nasacort and hemovel. The company was founded in 2010 and is headquartered in Montréal, Canada. | Corporate Officer/Principal | - |
Formazione di Mathieu Boudreau
| McGill University | Doctorate Degree |
| University of Montréal | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| FORESEE PHARMACEUTICALS CO., LTD. | Health Technology |
| Aziende private | 4 |
|---|---|
Telesta Therapeutics, Inc.
 Telesta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Telesta Therapeutics, Inc. is a biotechnology company, which focuses on the licensing/acquisition and development of transformational therapeutics for the treatment of serious human diseases, such as cancer, immune diseases, and targeted rare diseases. The company was founded by Graeme McRae in 1979 and is headquartered in Pointe-Claire, Canada. | Health Technology |
Pendopharm, Inc.
Pendopharm, Inc. Pharmaceuticals: MajorHealth Technology Pendopharm, Inc. is engaged in licensing, partnering, developing and marketing prescription medicines. Its products include Lax-A, helixia, Nasacort and hemovel. The company was founded in 2010 and is headquartered in Montréal, Canada. | Health Technology |
Pharmascience, Inc.
Pharmascience, Inc. Pharmaceuticals: MajorHealth Technology Pharmascience, Inc. manufactures and distributes generic and drug products. It offers liquids, tablets, capsules, suppositories, powders, and ophthalmic. The company was founded by Morris Goodman and Ted S. Wise in 1983 and is headquartered in Montr?al, Canada. | Health Technology |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Health Technology |
- Borsa valori
- Insiders
- Mathieu Boudreau
